NPI 1346766169: Open Payments
NPI 1346766169. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,179 in 64 payments from 19 companies in 2025. Trend: 2023 $1,455 · 2024 $1,527 · 2025 $1,179
Food & beverage: $1,179
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 10 | $190 |
| Novo Nordisk Inc | 12 | $185 |
| PFIZER INC. | 8 | $133 |
| AstraZeneca Pharmaceuticals LP | 5 | $91 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $78 |
| Lilly USA, LLC | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| Sumitomo Pharma America, Inc. | 3 | $50 |
| Lundbeck LLC | 2 | $48 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
Products named: TRELEGY ELLIPTA, NURTEC ODT, REXULTI, Rybelsus, XIFAXAN, MOUNJARO, Ozempic, GEMTESA.
